Source-grounded facts extracted from P3 Health Partners Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
P3 Health Partners Inc. received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).
“May 20, 2026, the Company received a letter from the Staff notifying the Company that, based on the Company’s Form 8-K filed with the SEC on May 15, 2026, the Staff has determined that the Company complies with Nasdaq Li”
P3 Health Partners Inc. reported financial results for the fourth quarter ended December 31, 2025.
“P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance.”
P3 Health Partners Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, P3 Health Partners Inc. (the “Company”) announced its financial results for the year ended December 31, 2025.”
P3 Health Partners Inc. entered into Statement of Work with a large nonprofit health insurance provider in the state of Nebraska (effective 2026-03-19).
“Effective as of March 19, 2026, P3 Health Partners, LLC (the “Company”) entered into a Statement of Work (the “SOW”) with a large nonprofit health insurance provider in the state of Nebraska (the “Client”), which incorporates the terms of a Master Services Agreement between the parties (the (the “MSA,” and together with the SOW, the “Agreements”).”
P3 Health Partners Inc. amended Amendment to Unsecured Promissory Note with VBC Growth SPV 5, LLC valued at $19.0 million (effective 2026-02-11).
“On February 11, 2026, P3 Health Group, LLC (the “Company”) entered into an Amendment to Unsecured Promissory Note (the “Amendment”) with VBC Growth SPV 5, LLC (the “Holder”) amending the terms of the Unsecured Promissory Note originally dated May 29, 2025 (the “Note). The Amendment modifies Section 1, clause (a)(iii) of the Note to extend the availability period for the third tranche of funding. Under the Amendment, the remaining $19.0 million of the third tranche is available for one or more draws through June 30, 2026.”
P3 Health Partners Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 21, 2025, P3 Health Partners Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does”
P3 Health Partners Inc. incurred loan of up to $70.0 million with VBC Growth SPV 5, LLC at 19.5% per annum maturing August 13, 2028.
“independent, disinterested directors of the Company. VBC 5 Promissory Note The Promissory Note was issued by P3 LLC to VBC 5 on May 29, 2025, and provides for funding of up to $70.0 million (the “Promissory Note”), available for draw by P3 LLC in tranches, as follows: (i) a first tranche of $15.0 million available to P3 LLC upon the Effective Date, (ii) a second”
Atul Kavthekar resigned as Chief Financial Officer at P3 Health Partners Inc..
“Mr. Pedersen will succeed Atul Kavthekar, who resigned from his position as Chief Financial Officer of the Company effective as of the Effective Date.”
Leif Pedersen was appointed as Chief Financial Officer at P3 Health Partners Inc..
“On August 29, 2024, the Board of Directors (the “Board”) of P3 Health Partners Inc. (the “Company”) appointed Leif Pedersen as Chief Financial Officer of the Company, effective as of October 1, 2024 (the “Effective Date”).”
Sherif Abdou was appointed as Vice Chairperson of the Board and Senior Advisor at P3 Health Partners Inc..
“the Board appointed Dr. Abdou as Vice Chairperson of the Board. Dr. Abdou will serve as Senior Advisor to the Company’s board of directors and Chief Executive Officer”
Sherif Abdou resigned as Chief Executive Officer and President at P3 Health Partners Inc..
“Dr. Coffman succeeds Sherif Abdou, M.D., who resigned from his positions as Chief Executive Officer and President of the Company effective as of the Effective Time.”
Aric Coffman was appointed as Chief Executive Officer and President at P3 Health Partners Inc..
“appointed Aric Coffman, M.D. as Chief Executive Officer and President of the Company, effective at 12:00 p.m. Eastern Time on May 8, 2024”
P3 Health Partners Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 8, 2024, P3 Health Partners Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.